More recently, LCMT-1 Tg mice showed resistance against amyloid β-protein (Aβ) injury, indicating that LCMT-1 or PME-1 can be used as a target for treatment of neurodegenerative diseases (Nicholls et al., 2016). The gene discussed is LCMT1; the disease is neurodegenerative disease.